This most recent twist while in the Lykos Therapeutics saga threatens a major overhaul of the company’s technique and path, with Musk ally and billionaire investor Antonio Gracias showing up to want to take the business back towards its nonprofit drug development roots and a more Doblinite philosophy.“This may have transpired before, even when